Clinical Trial Update: A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma [Phase 1]

View source ↗

Summary

Phase Ib trial evaluating the MVA-EBNA1/LMP2 vaccine for nasopharyngeal carcinoma has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epstein-barr Virus Infection
• Nasopharyngeal Carcinoma

Drugs mentioned

• MVA-EBNA1/LMP2 vaccine (MVA-EBNA1/LMP2 vaccine)

Snippet

Sponsor: Cancer Research UK | Conditions: Nasopharyngeal Cancer, Epstein Barr Virus Infections | Phase 1 | Status: COMPLETED